Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CES 2016: Consumer and Medical Devices Come Together in Digital Health

Executive Summary

The role digital health will ultimately play in the overall health care market is still evolving, but it is becoming clearer that consumers and consumer-based products will play a role. The merging of consumer and medical was evident at CES in Las Vegas, where an increasing number of businesses are showcasing new products for the digital health market, which is expected to reach $233 billion by 2020.

You may also be interested in...



The Digital Health Care Revolution Picks Up Speed

The excitement about digital health solutions has reached new heights as the market moves toward changes where those solutions are not only wanted, but in many cases needed to help battle costs and improve patient outcomes. The interest in digital health is part of a larger trend that is seeing patients take on more and more responsibility for their own health amid changing perceptions of what is considered a medical device.

IBM Forms Health Company, Forges Partnerships With Apple, J&J, And Medtronic

Computing giant IBM has become the latest tech company to move into the health care space, setting up a dedicated business unit, IBM Watson Health, and signing up a slew of big-hitting partners.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel